MANILA, PHILIPPINES – Media OutReach Newswire – 13 October 2026– VinFast has officially opened pre-orders for the all-new VF 8 in the Philippines, the first international market to introduce the D-segment electric SUV. Developed on a new-generation technology platform, the VF 8 is designed to elevate the driving experience. Interested customers can register through VinFast’s authorized dealerships nationwide. The first 1,000 customers who place pre-orders from today through November 5, 2026, will receive a free one-year battery subscription.
The VinFast VF 8 is now available for pre-order in the Philippines, further expanding the brand’s product lineup and offering customers more choice.
The VF 8 is VinFast’s all-new D-segment electric SUV and will be introduced in the Philippine market. Developed with comprehensive advancements in design, technology platform, features, and driving experience, the VF 8 is designed to deliver a modern, comfortable, and intelligent mobility experience that meets the increasingly diverse needs of Filipino customers.
In terms of design and comfort, the all-new VF 8 is developed around the “Tech Fluid” design philosophy, focusing on seamless lines, sophistication and a strong sense of motion. The overall design combines technology, emotion and everyday practicality in a modern, dynamic package.
Alongside its technology and performance upgrades, the all-new VF 8 offers added peace of mind with a vehicle warranty of seven years or 160,000 km and a battery warranty of 10 years or 200,000 km.
From now through November 5, 2026, Philippine customers can place a deposit for the all-new VF 8 through VinFast’s authorized dealerships nationwide, with a non-refundable deposit of PHP 5,000-10,000. The first 1,000 customers who place their deposits during this period will receive a complimentary one-year battery subscription.
The all-new VF 8 will officially launch in the Philippines in November 2026, with the first vehicles expected to be delivered starting the same month.
Antonio “Toti” Zara III, CEO of VinFast Philippines, said: “The tremendous demand for VinFast’s innovations here in the Philippines inspired us to launch this early booking program for the all-new VF 8. Built for the performance and tech-focused Filipinos, the VF 8 promises a premium midsize crossover e-SUV experience. The pre-order program is our way of giving Filipinos a chance to be among the first in the Philippines to experience our newest offering. We cannot wait for the arrival of the VF 8 in the Philippines this November, and we are even more excited to welcome more Filipinos to the VinFast ecosystem.”
VinFast is building a comprehensive “For a Green Future” EV ecosystem across key markets in Southeast Asia. In the Philippines, the launch of the all-new VF 8, together with VinFast’s diverse EV lineup and customer support policies, further strengthens the foundation for the company’s development in the market. VinFast is also investing in after-sales services and charging infrastructure with the support of V-Green and local partners, providing practical benefits, helping reduce ownership costs and making EV ownership more convenient, while contributing to the Philippines’ transition toward greener mobility./.
Hashtag: #VinFast
The issuer is solely responsible for the content of this announcement.
For the first time, Orbius customers can deploy a single, fully integrated stack through the StarEDGE platform: Multi-LEO satellite connectivity paired with Armada’s modular data centers, bringing edge computing and artificial intelligence to remote operations worldwide
FORT LAUDERDALE, Fla., Oct. 13, 2026 /PRNewswire/ — Orbius Communications, a world-class Multi-LEO (Low Earth Orbit) operator that combines satellite, terrestrial, and cloud networks into a single architecture, announces a new edge cloud solution that integrates its StarEDGE platform with Armada’s powerful edge computing infrastructure. The result is the first fully unified offering that spans connectivity through multiple satellite constellations and compute end to end, from the network link to the AI workload running at the edge, deployed and managed as a single system.
For enterprises and governments, this means artificial intelligence is no longer confined to centralized cloud infrastructures. As an official partner in Armada’s ecosystem, Orbius can now help companies process data, make decisions at the speed of the mission, and scale from a single remote site to a full global footprint of interconnected AI nodes, while keeping data sovereign at every step. That sovereignty is backed by Orbius’s Private Network Interconnect (PNI) footprint, a global private network leveraging LEO satellite constellations, which carries customer traffic over Layer 2 paths terminating at regional data centers rather than the public internet, so that data stays on secure infrastructure from the satellite link all the way to the edge workload.
Edge computing is one of the fastest-growing segments in enterprise, with global spend projected to nearly triple by 2031 to more than USD 317 billion according to initial studies1, as organizations push artificial intelligence and real-time processing out of centralized data centers and into the field. For industries operating in remote or regulated environments, such as maritime, telecommunications, energy, mining and others, deploying that compute alongside carrier-grade multi-LEO connectivity, engineered for Six Sigma uptime, is a key strategic advantage to unlock the full value of AI across their operations.
“For too long, multiple critical remote workloads -keeping a vessel running, a grid online, remote assets under 24/7 supervision- have been held back by a lack of connectivity and real-time compute. That era is ending,” said Halldor Sigurdsson, CEO at Orbius. “By pairing our StarEDGE Multi-LEO platform with Armada’s solutions, remote is no longer a limitation. Wherever our customers operate, on land or at sea, they now can have high-speed connectivity and the full power of AI at the edge.”
“With Orbius, Armada has a historic opportunity to remove a long-standing burden between satellite and compute vendors,” said Dan Wright, Co-founder and CEO of Armada. “From open-ocean maritime to conflict zone and disaster-relief deployments, our combined offering gives customers one partner across the full chain from signal to decision, instead of stitching together solutions themselves.”
With the Orbius-Armada Full-Stack Solution, customers get:
Speed to operational value: AI-ready operations deployed in weeks instead of the years required for traditional data centers, so operations start generating value almost immediately
A solution built for the edge: ruggedized, modular, transportable infrastructure paired with global Multi-LEO, 5G/LTE, and HTS connectivity, purpose-built for remote field conditions
Sovereign by design: data and decision-making stay on-site, within the organization or within national borders, meeting compliance and control requirements of regulated industries
Scaling with the mission: enterprises can start with a single site and expand to a full global fleet as operations grow, without re-architecting connectivity or compute in the process
One accountable partner, start to finish: a single relationship spanning network and compute, delivered through standardized integrations, secure APIs, proactive NOC monitoring and contractual SLAs, removing the integration risk and vendor coordination complexities
This solution is available now to customers across maritime, energy, government, telecommunications and enterprise markets, supported by Orbius offices in the United States, Iceland, Brazil, Ireland, France, Spain, Norway and the UAE, among others. For more information, visit Orbius.com.
About Orbius Built on the new digital economy and the Low Earth Orbit satellite revolution, Orbius is a world-class Multi-LEO operator that unifies satellite and terrestrial networks into one cutting-edge Network-as-a-Service (NaaS) platform to optimize enterprise connectivity. We provide satellite solutions and edge computing power to process data and enable AI everywhere, including the most remote corners of the world. As a trusted expert and managed-service partner, we help companies integrate satellite, terrestrial, and cloud networks together with edge computing platforms, so operations run with unmatched efficiency, resilience, and control. For more information, visit Orbius.com or StarEDGE.com.
About Armada Armada is the hyperscaler for the edge, delivering modular AI infrastructure from first deployment to AI factory with speed, scale, and sovereignty. For more information, visit www.armada.ai.
CHENGDU, China, Oct. 13, 2026 /PRNewswire/ — The 2026 European Society for Medical Oncology (ESMO) Congress will be held in Madrid, Spain, from October 23 to 27. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun-Biotech” or the “Company”, 6990.HK) will present results from multiple clinical studies at the congress, including data from its trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870)(佳泰莱®) and another ADC.
Among them, multiple research findings for sac-TMT have been selected for oral presentations, including the Phase III OptiTROP-Lung04 and OptiTROP-Lung06 studies, which have both been selected for the “Non-Small Cell Lung Cancer (NSCLC), Metastatic” session and will be presented in the same time slot as proffered paper reports. In addition, data from the global pivotal Phase III TroFuse-005 trial led by MSD[1] will be presented for the first time in the ESMO Presidential Symposium.
The abstract titles of the above studies as well as other studies from Kelun-Biotech have been published on the official ESMO website. Details are as follows:
Lung cancer
Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus chemotherapy (chemo) plus pembrolizumab (P) as first-line (1L) treatment for PD-L1 negative advanced non-squamous (nsq) NSCLC: randomized phase 3 OptiTROP-Lung06 study
LBA66, Proffered paper | NSCLC, metastatic
October 25, 10:15 to 11:45 local time
Final OS analysis of sacituzumab tirumotecan (sac-TMT) versus platinum-based chemotherapy in EGFR-mutated non-small cell lung cancer (NSCLC) after progression on EGFR-TKI: phase III OptiTROP-Lung04 study
LBA67, Proffered paper | NSCLC, metastatic
October 25, 10:15 to 11:45 local time
SKB500 (a novel B7-H3–targeted antibody-drug conjugate) in patients with extensive-stage small cell lung cancer (ES-SCLC): Results from a Phase I study
3816RO, Rapid oral | Non-metastatic NSCLC and other thoracic malignancies
October 26, 10:15 to 11:45 local time
Breast cancer
Final OS analysis of sacituzumab tirumotecan versus chemotherapy in previously treated locally recurrent or metastatic triple-negative breast cancer: Phase III OptiTROP-Breast01
4639RO, Rapid oral | Breast cancer, advanced stage
October 26, 10:15 to 11:45 local time
Gynecologic cancers
Sacituzumab tirumotecan in previously treated advanced or recurrent endometrial cancer: Results from the Phase 3 TroFuse-005/ENGOT-en23/GOG-3095 study
LBA11, Proffered Paper | Presidential Symposium
October 26, 16:30 to 18:15 local time
Sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) in post-platinum advanced mismatch repair proficient (pMMR) endometrial cancer (EC): Results from a Phase 2 study (2870-002/SKB264-II-06)
1259P, Poster | Gynaecological cancers
October 26, 12:00 to 12:45 local time
Genitourinary cancers
Sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) for locally advanced or metastatic urothelial carcinoma (la/mUC): Results from a Phase 2 Study (2870-002/SKB264-II-06)
4739RO, Rapid oral | Genitourinary tumours, renal and urothelial
October 24, 10:15 to 11:45 local time
About sac-TMT(佳泰莱®)
Sac-TMT, a core product of the Company, is a novel TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, breast cancer (BC), gastric cancer (GC), gynecological tumors and genitourinary tumors, among others. Sac-TMT is developed with a unique, bifunctional linker that maximizes payload delivery to tumor cells both through its irreversible connection with the anti-TROP2 monoclonal antibody sacituzumab and its pH-sensitive cleavage from a belotecan-derivative topoisomerase I inhibitor payload (KL610023) in the lysosome, with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases the payload KL610023 intracellularly. KL610023 induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells.
In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc, Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (which includes Mainland China, Hong Kong, Macao and Taiwan).
To date, four indications for sac-TMT have been approved and marketed in China for: 1) unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting); 2) epidermal growth factor receptor (EGFR) mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy; 3) EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC who progressed after treatment with EGFR-TKI therapy; 4) unresectable or metastatic hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) (Immunohistochemistry (IHC) 0, IHC 1+ or IHC 2+/In Situ Hybridization (ISH)-) BC who have received prior endocrine therapy and at least one line of chemotherapy in advanced setting. The first two indications above have been included in China’s National Reimbursement Drug List (NRDL). This inclusion is expected to bring clinically meaningful benefits to a greater number of patients with BC and NSCLC. Additionally, sac-TMT has been granted six Breakthrough Therapy Designations by the NMPA.
Sac-TMT is the world’s first TROP2 ADC drug approved for marketing in lung cancer. Two new indication applications have been accepted for review by the NMPA: 1) sac-TMT in combination with pembrolizumab as first‑line treatment for locally advanced or metastatic NSCLC who have programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥1% and are EGFR-negative and ALK-negative; 2) sac‑TMT as first‑line treatment for patients with recurrent or metastatic TNBC who have a PD‑L1 combined positive score (CPS) <10 or have recurred after prior programmed cell death protein 1 (PD-1)/PD‑L1 inhibitor therapy in the early stage, both of the above two applications have been included in the priority review and approval process. As of today, the Company has initiated 9 registrational clinical studies in China. MSD has initiated 18 ongoing global Phase III clinical studies of sac-TMT as a monotherapy or in combination with pembrolizumab or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD.
About SKB500
SKB500 is a B7-H3-targeted ADC independently developed by the company using its OptiDCTM platform technology, featuring a site-specific cleavable linker and a potent topoisomerase I inhibitor. In the Phase I clinical study, SKB500 demonstrated robust efficacy and manageable safety profiles across multiple advanced solid tumors. Currently, two Phase II studies of SKB500 in extensive-stage small cell lung cancer (ES-SCLC) and advanced esophageal squamous cell carcinoma (ESCC),etc. are ongoing in China.
About Kelun-Biotech
Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects with 8 indications have been approved for marketing, 2 projects with 3 indications are in the NDA stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world’s leading proprietary ADC and novel DC platforms, OptiDCTM, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit: https://en.kelun-biotech.com/.
[1] MSD is the tradename of Merck & Co., Inc, Rahway, NJ, USA.
Hiteck grants Visara, a majority-owned ophthalmology subsidiary of NovaBridge Biosciences (NASDAQ: NBP), exclusive worldwide rights, excluding Greater China, to develop and commercialize HT006.2.2
Hiteck retains all rights in Greater China, where a Phase 1b study in severe neurotrophic keratitis showed 50% complete corneal healing in the highest dose cohort after an 8-week course
HT006.2.2 is designed to offer a more convenient treatment option for patients with neurotrophic keratitis, building on Hiteck’s longstanding expertise in nerve growth factor (NGF) therapeutics
WUHAN, China, Oct. 13, 2026 /PRNewswire/ — Wuhan Hiteck Biological Pharma Co., Ltd. (“Hiteck”) (SZSE: 300683) today announced that it has entered into an exclusive license agreement (the “License Agreement”) with Visara, Inc. (“Visara”), a majority-owned ophthalmology subsidiary of NovaBridge Biosciences, for HT006.2.2, an investigational next-generation modified recombinant human nerve growth factor (rhNGF) eye drop being developed for the treatment of neurotrophic keratitis (NK). Visara plans to develop HT006.2.2 as VIS-102.
Under the terms of the License Agreement, Visara will receive exclusive rights to develop and commercialize HT006.2.2 worldwide excluding Greater China, and Hiteck retains all rights in Greater China. Hiteck will receive an upfront payment and is eligible to receive development, regulatory and commercial milestone payments, as well as tiered royalties on net sales. A joint steering committee (JSC) will be responsible for the oversight and coordination of research and development activities under the License Agreement, technology transfer, management of the global development plan and expansion studies, information exchange, and such other functions as the parties may agree in writing.
In NK, damage to the corneal nerves impairs the eye’s ability to heal, which can lead to persistent epithelial defects, corneal ulceration and permanent vision loss. Hiteck discovered and designed HT006.2.2 to make NGF therapy more practical for patients and caregivers, drawing on its experience with Aneway (Jinlujie), an NGF therapy that has benefited millions of patients in China. Through targeted modifications to the NGF amino acid sequence and formulation optimization, HT006.2.2 is designed to improve resistance to enzymatic degradation and remain stable under refrigeration, with formulation stability superior to that of existing products in the same class. This design may allow HT006.2.2 to potentially be supplied in ready-to-use, single-dose units, potentially easing the storage, shipping, handling and administration demands of current NK treatments.
HT006.2.2 showed a favorable safety profile in a first-in-human Phase 1 study, the results of which were published in the European Journal of Pharmaceutical Sciences. In a subsequent Phase 1b study in Chinese subjects with severe NK:
In the highest dose cohort, 50% of subjects achieved complete corneal healing after a single 8-week course of HT006.2.2, compared with 14% of subjects in the vehicle control group at Week 4.
Subjects on vehicle then crossed over to active treatment from Week 5 to Week 8, and 43% achieved complete corneal healing after a 4-week course of HT006.2.2.
Treatment-related ocular adverse events were all mild and consistent with trials of rhNGF. No subjects withdrew or discontinued the study due to a related adverse event.
The study will continue with an expansion phase evaluating the highest dose at both 6 times daily and 3 times daily 8-week regimens in Chinese patients with NK.
“Nerve growth factor has long been central to Hiteck’s science, and HT006.2.2 represents the next generation of that work, designed for stability and everyday practicality at the ocular surface,” said Ya Chen, Chairman of Hiteck. “Visara’s dedicated ophthalmology focus and global development capabilities make it a strong partner to advance this program internationally. This agreement is an important step in Hiteck’s international strategy, and we look forward to working closely with Visara as we continue development in Greater China.”
About HT006.2.2 HT006.2.2 is an investigational modified recombinant human nerve growth factor eye drop being developed for the treatment of neurotrophic keratitis. It has been evaluated in a first-in-human Phase 1 study and in a Phase 1b study in China, which will continue with an expansion phase. Its targeted amino acid sequence modifications and optimized formulation are intended to enhance resistance to enzymatic degradation and support stability at refrigerated temperatures, enabling a ready-to-use, single-dose format. Hiteck holds the rights to HT006.2.2 in Greater China, and Visara holds exclusive rights in the rest of the world, where the program will be developed as VIS-102.
About Neurotrophic Keratitis Neurotrophic keratitis is a rare, degenerative corneal disease that occurs when the sensory nerves supplying the cornea are damaged. It can result from conditions such as herpetic eye infection, diabetes, or ocular and neurosurgical procedures. Without normal nerve function, the corneal surface loses both sensation and the trophic support it needs to repair itself. Over time, the disease can progress from persistent epithelial defects to corneal ulceration, stromal melting and perforation, and may result in permanent vision loss.
About Hiteck Wuhan Hiteck Biological Pharma Co., Ltd. was founded in 1992 at the Medical School of Wuhan University and is a publicly listed biopharmaceutical company on the Shenzhen Stock Exchange (stock code: 300683). Guided by its mission of “Innovating for Life,” Hiteck focuses on oncology, neurology and immunology, with a continued commitment to the development of innovative biologics and small molecule therapeutics. In oncology, Hiteck developed Aponermin, the world’s first approved DR4 and DR5 agonist, which received regulatory approval in 2023 and was rapidly included in China’s National Reimbursement Drug List (NRDL), introducing a novel therapeutic target for patients with relapsed or refractory multiple myeloma. In neurology, the company translated Nobel Prize-winning discoveries into clinical practice with Aneway (Jinlujie), one of the first nerve growth factor (NGF) therapies approved for clinical use, which has benefited millions of patients. Hiteck is also advancing HiTrans™, a transferrin receptor (TfR)-based brain delivery platform designed to facilitate the transport of therapeutics across the blood-brain barrier, with potential applications in central nervous system (CNS) diseases. For more information, please visit www.hiteckpharma.com.
About Visara Visara is a clinical stage biotechnology company dedicated to developing next-generation biologic therapies for ophthalmic diseases affecting both the front and back of the eye. From the cornea to the retina, Visara pursues the full spectrum of ocular disease as vision is irreplaceable, and the unmet need is profound. Visara is a majority-owned ophthalmology subsidiary of NovaBridge Biosciences (NASDAQ: NBP). Its pipeline includes VIS-101, a tetravalent VEGF-A × ANG-2 peptibody being developed for neovascular retinal diseases, and VIS-102, a next-generation modified recombinant human nerve growth factor therapy being developed for neurotrophic keratitis.
Forward-Looking Statements This press release contains forward-looking statements, including statements regarding the potential benefits of HT006.2.2, the clinical development plans and timing for HT006.2.2, and the anticipated achievement of milestones and receipt of payments under the License Agreement. Words such as “will,” “expects,” “believes,” “designed to,” “intends,” “plans,” “potential” and similar expressions are intended to identify forward-looking statements. These statements are based on current expectations and are subject to risks and uncertainties, including uncertainties inherent in clinical development, regulatory review and commercialization, which may cause actual results to differ materially. Milestone and royalty payments are contingent on future events and may not be received in full or at all. Hiteck undertakes no obligation to update any forward-looking statements, except as required by applicable law.
BRASILIA, Brazil, Oct. 13, 2026 /PRNewswire/ — Dept, a South Korean singer-songwriter affiliated with unikorn union Inc. and Brazilian artist IVYSON affiliated with Babel Produções are joining forces for a collaboration presented in English and Portuguese. Their English-language release, “We Talk,” arrives on Oct 14, 2026, followed by its Portuguese-language Brazilian counterpart, “Lembra,” on Oct 22, 2026.
South Korean singer-songwriter and producer Dept and Brazilian artist IVYSON are joining forces for a collaboration presented in English and Portuguese.
Dept has built an international audience through songs such as “Strawberry Champagne,” “Green,” “Van Gogh,” “Whenever It Rains” and “Winter Blossom.” His smooth, polished melodies and emotionally driven lyrics have helped his music connect with listeners across Asia and beyond.
His international collaborations include work with American artist Ashley Alisha, Thai singer NONT TANONT and Vietnamese singer Hoàng Dũng. This latest project brings that spirit of musical exchange to Brazil through his collaboration with IVYSON, pairing Dept’s emotional R&B and indie-pop approach with a new creative partnership across languages.
The lyrics of “We Talk” explore the quiet distance between two people trying to talk about love. Images of neon light, rain and hesitant conversation create an intimate, reflective mood, with the recurring question at the heart of the song expressing the uncertainty of a fragile connection.
The collaboration extended beyond the recording process. During Dept’s visit to Brazil, the two artists met in person to film the project’s music video, bringing their musical exchange into a shared visual production on location.
During the same visit, Dept also met fans in São Paulo, creating a direct connection with Brazilian listeners. The project continues his work with artists across different countries, connecting Korea and Brazil through music and visual storytelling.
“We Talk,” credited to Dept and IVYSON, will be available across major music streaming platforms. The Portuguese-language “Lembra” is credited to Dept and IVYSON.
Senior appointments strengthen Convera’s ability to help customers move money globally with greater speed, visibility, and control.
SEATTLE and LONDON, Oct. 13, 2026 /PRNewswire/ — Convera, a global leader in commercial payments, today announced four senior leadership appointments: Mike Cahill as EVP and Chief Operating Officer; Jon Southall as SVP and Chief Technology Officer; Tui Allen as SVP and Chief Product Officer; and Chris Steinig as Chief Information Officer. Together, they bring extensive experience in building and scaling global payments, product, technology and operational platforms. They will lead the execution of Convera’s roadmap for an integrated global money movement platform that combines cross-border payments, FX risk management and multi-currency capabilities for businesses.
Pictured L-R: Mike Cahill, EVP and Chief Operating Officer; Jon Southall, SVP and Chief Technology Officer; Tui Allen, SVP and Chief Product Officer; and Chris Steinig, Chief Information Officer.
Convera’s strategy is built on a simple premise: as agentic commerce emerges and volatility persists, businesses operating across borders need integrated solutions. They need to send, receive and hold money in the currencies they trade in, manage FX exposure at the point of payment, and route transactions across the most appropriate payment rail for speed, cost and visibility.
“Businesses don’t just need faster or less expensive cross-border payments. They need to know where their money is, what it is worth and how to protect it as it moves,” said Patrick Gauthier, Group CEO at Convera. “That is the opportunity in front of Convera. Our global reach, FX expertise, regulatory depth and customer relationships enable us to solve that problem in a way few providers can. Mike, Jon, Tui and Chris are proven leaders with the experience, judgement and execution discipline to help us deliver for customers. Each brings a distinct perspective, and together they give us the leadership depth to advance our roadmap for integrated cross-border money movement.”
Advancing customer-led execution
Mike Cahill has been appointed EVP and Chief Operating Officer, leading Convera’s combined Product, Technology and Operations organization. Since joining Convera in June 2026 as Interim Chief Product and Technology Officer, he has focused on bringing these functions together to deliver a more connected customer experience. Cahill has scaled mission-critical financial platforms and led complex transformations at Early Warning Services, the company behind Zelle, as well as at PayPal, Boku and American Express.
Jon Southall joins as SVP and Chief Technology Officer from PayPal, where he managed the Large Enterprise Platform, which supports more than $1.5 trillion in annual transaction volume. He has also built scaled payment platforms at Boku and Braintree. His experience in high-volume infrastructure will help Convera deliver faster, more reliable and more visible money movement for customers.
Tui Allen joins as SVP and Chief Product Officer from Ticketmaster/Live Nation, where she helped modernize product experiences at scale. She previously built new solutions at Shopify. Allen brings experience translating complex customer needs into scalable products that are easier to use, integrate and adopt.
Chris Steinig has been appointed Chief Information Officer after leading Convera’s technology operations. A 25-year veteran of the company, he brings deep knowledge of Convera’s systems, infrastructure and operating environment. Steinig will connect platform modernization, enterprise technology and operational resilience to help ensure the company delivers its roadmap with the reliability and control customers expect.
“This team brings complementary strengths across product, technology and operations, backed by experience delivering at global scale,” said Mike Cahill, EVP and Chief Operating Officer at Convera. “Our focus is disciplined execution: translating customer needs into products, modernizing the technology that supports them and delivering consistently in every market we serve. That is how we will make cross-border money movement simpler, more connected and more valuable for our customers.”
These appointments build on Convera’s continued investment in technology, product delivery and commercial capabilities. This includes Multi-Currency Accounts and APIs that allow banks, fintechs and business platforms to embed Convera’s payments and FX risk management capabilities into their own customer experiences.
About Convera
Convera is a global leader in commercial payments, helping businesses and institutions navigate the complexity of global commerce. It combines technology-led payment solutions with deep expertise in foreign exchange, risk management and compliance to help organizations manage cross-border payments with greater confidence. With an unrivalled regulatory footprint, a financial network spanning more than 140 currencies and 200 countries and territories, and nearly $200 billion in annual payment flows, Convera helps organizations move money globally with greater control, certainty and trust.
SHENZHEN, CHINA – Media OutReach Newswire – 13 October 2026 – Global smart device brand OPPO today announced a collaboration with Manus, a leading AI agent platform, to bring next-generation agentic AI experiences to smartphones. By integrating Manus’ agentic capabilities to OPPO AI Mind Pilot, the collaboration will help users turn complex, multi-step tasks into ready-to-use results—advancing OPPO’s vision for Personalized Proactive Intelligence, where AI understands users and proactively helps them get things done.
“Agentic AI marks an important shift from answering questions to helping users get things done.” said Kai Tang, President of Software Engineering at OPPO. “Together with Manus, we are bringing more proactive and capable experiences to AI Mind Pilot, enabling AI to better understand users’ intentions, take actions and complete tasks. Our goal is to make personal AI a natural part of everyday life and work.”
“Smartphones are central to people’s daily lives and support many of the tasks they handle every day, making them a natural platform for personal AI agents,” said Tao Zhang, Co-Founder & CPO of Manus. “By bringing together Manus’ agentic capabilities and OPPO’s system-level integration, we can make advanced AI agents more accessible and help users complete multi-step tasks through simple, natural interactions.”
Manus Capabilities Debut in AI Mind Pilot’s New Agent Mode
The collaboration will debut through the integration of Manus’ agentic capabilities into AI Mind Pilot’s new Agent Mode on the upcoming OPPO Find X10 Series with ColorOS 17.
Designed to move beyond simple question-and-answer interactions, AI Mind Pilot can understand a user’s end goal, break it down into multiple steps, identify relevant information, select the appropriate tools, and deliver a finished result, including by working directly with files and photos stored on the device.
For example, a user planning a trip could simply ask AI Mind Pilot to organize their travel plans. It can find flight tickets, hotel bookings, restaurant reservations, and attraction tickets scattered across different apps on the smartphone, organize them, and combine them with relevant online information to create a personalized, day-by-day itinerary—without requiring users to manually gather and upload the information.
The same capabilities can support everyday creative and professional tasks. Users can ask AI Mind Pilot to find and organize photos from a trip, locate specific images, or bring together existing files and online information to create a presentation, proposal, portfolio, or other ready-to-use content, all with just one single prompt.
Powerful Agentic AI Built Around User Control and Privacy
As AI moves from providing information to working with personal context and completing tasks, privacy, security, and user control become increasingly important. AI Mind Pilot is designed with these priorities at its core.
ColorOS 17 uses on-device models to understand and organize relevant information locally. For local tasks such as finding, organizing, or renaming files and photos, the original content remains on the device and is not shared with Manus. When a task requires external processing, AI Mind Pilot will ask for the user’s explicit confirmation before relevant content is uploaded or shared.
Users remain in control of what information is accessed, which actions are taken and whether external processing is allowed. Through on-device processing and transparent authorization, OPPO and Manus aim to make agentic AI more capable while maintaining a clear fucus on users’ choice and control.
Launching on OPPO Find X10 Series
The Manus-powered capabilities in AI Mind Pilot will debut on the OPPO Find X10 Series with ColorOS 17. Further details on availability, supported markets, and user benefits will be announced at launch.
Hashtag: #OPPO
The issuer is solely responsible for the content of this announcement.
SHENZHEN, CHINA – Media OutReach Newswire – 13 October 2026 – OPPO today unveiled ColorOS 17, the latest generation of its mobile operating system, delivering a new level of smoothness alongside more intelligent, system-level AI capabilities. Debuting on the upcoming Find X10 Series and rolling out progressively to more OPPO devices, ColorOS 17 will bring these new experiences to users worldwide.
Flow Everywhere
From Parallel Animation in ColorOS 15 to Seamless Animation in ColorOS 16, smoothness has long been a defining quality of ColorOS. With ColorOS 17, OPPO takes this further, introducing the all-new Living Flow Design to make every interaction feel even more natural, continuous and responsive.
Living Flow Design is built around three core ideas: Luminous Effect, Fluid Motion and Flexible Feedback. Luminous Effect introduces softer, more translucent visuals, creating a refined sense of depth and hierarchy, while subtle lighting naturally guides attention and responds to touch. Fluid Motion enables interface elements to move, merge and transform seamlessly from one state to the next, with this sense of continuity carried throughout the system. Flexible Feedback brings the same sense of responsiveness to touch. Buttons, toolbars and other interactive elements visibly compress, stretch and rebound in response to taps, giving each interaction a more immediate and tactile feel rather than a mechanical response. Together, these elements create a more fluid and cohesive experience across the system, making everything from app transitions and Fluid Cloud to everyday interactions feel more immediate and intuitive.
To make this experience consistent across the system, ColorOS 17 introduces a Unified Rendering Architecture built on the refreshed Luminous Rendering Engine. By bringing previously separate rendering processes into a unified pipeline, the new architecture not only enables richer visual effects and more continuous transitions, but also reduces redundant rendering operations for greater efficiency. In key scenarios, it cuts rendering loads by up to 30% and RAM usage for rendering by up to 25% compared with the previous generation, helping interactions remain smooth even under heavy load.
Beyond visual rendering, ColorOS 17 also improves system-level responsiveness with the upgraded Laminar Flow Engine, an intelligent resource scheduling system built to handle increasingly complex mobile workloads. Built on OPPO’s Adaptive Scheduling Architecture, it coordinates foreground and background workloads as part of a unified flow, delivering consistently smooth performance across both everyday use and demanding scenarios.
With the Laminar Flow Engine, app launch stability improves by 55%, while Gallery thumbnails load up to 50% faster on first launch compared with ColorOS 16. During multitasking, ColorOS 17 can also keep over 25% more apps running in the background, helping users switch between apps more smoothly. 1
And smoothness is not only about how a phone performs today, but how well that experience holds up over time. In tests simulating six years of use, ColorOS 17 retains over 90% of its initial smoothness, even with storage at 90% capacity. 1
OPPO AI, Flow with Your Mind
ColorOS 17 expands OPPO AI with system-level agentic capabilities designed not only to answer questions, but also to help users complete complex tasks.
With ColorOS 17, AI Mind Pilot introduces a new Agent Mode that can work directly with photos and files stored on the device, search across multiple sources, use the appropriate tools and coordinate multiple steps to complete tasks based on the user’s request. It can find and organize scattered files, rename them based on their content and date, and use the information within them to create new outputs such as travel itineraries or webpages. It can also find photos from a specific trip, sort them into albums, and even turn a selected photo into a vlog cover or adapt it for different creative needs.
ColorOS 17 also introduces AI Photo Agent, making photo editing more intuitive while staying true to the natural look and authentic character of the original scene. With Style Match, users can simply provide a reference image, and AI Photo Agent can understand its color palette, tone and overall mood before applying a similar look to their own photo. Users can also describe the edits they want in natural language, or let AI Photo Agent analyze the image and recommend suitable adjustments based on the scene and subject.
AI Mind Space, OPPO’s personal information hub, receives a major upgrade in ColorOS 17. Users can now save documents and video links, with AI recognizing their content and turning it into structured, searchable personal memories. As saved information grows, the new Memory Collections automatically organize related memories into useful collections and summaries. For travel, it can combine remembered content with destination maps to create personalized trip plans based on the places, ideas and information users have saved.
The new AI Mind Suggest brings useful information and services to users at just the right moment. From a morning brief and timely travel reminders to flight and train cards that surface key journey information, AI Mind Suggest proactively helps users stay on top of what matters throughout the day. It can also recommend music when headphones are connected, making useful services available when they are most relevant.
Meanwhile, OSee brings OPPO’s visual AI capabilities together into one integrated experience. With a single press of the camera shutter, OSee can intelligently understand objects and scenes in view and connect users to services such as object recognition, knowledge lookup, nutrition analysis, high-definition scanning and translation. Instead of choosing between multiple separate tools, users can go directly from what they see to the service they need.
Security, Always On
ColorOS continues to place user privacy and data protection at the core of its AI experiences. OPPO’s Private Computing Cloud protects data used for cloud-based AI processing with end-to-end encryption and processes it within a secure environment designed to prevent access by third parties, including OPPO. ColorOS 17 further strengthens data transmission security with new post-quantum security capabilities in PCC. When data is transmitted between the device and the cloud, a dual-encryption mechanism helps protect information against emerging threats posed by quantum computing.
A new Transparency Report in ColorOS 17 gives users greater visibility into how their data is processed. The report provides information including which AI services have been used, when they were accessed and what operations were performed. Users can view the report directly on their device and export it whenever needed.
Proactive protection is also strengthened with the new AI Call Guard. Powered by on-device AI detection, AI Call Guard monitors calls in real time for emerging fraud risks such as synthetic voices and AI face swaps, alerting users when suspicious activity is detected to help protect both their communications and personal information.
Availability
ColorOS 17 will debut on the upcoming OPPO Find X10 Series, with additional OPPO devices receiving the update progressively.
For detailed rollout information, please refer to the official ColorOS website.
[1] Data from OPPO Lab.
2AI Photo Agent will roll out gradually across multiple countries, with availability in Europe to follow at a later date. Monthly usage limits apply and vary by country or region. This feature supports static images only.
3Long-doc Capture and Link Capture are not available in Europe.
4 Certain features, like MakeMyTrip Train Card, flight information reminders and Spotify music recommendations are only available in certain countries and regions.
https://www.oppo.com
